Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

Citation

• Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N., De Souza, P. L., . . . Ryan, C. J. (2013). Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).. Journal of Clinical Oncology, 31(15_suppl), 5009. doi:10.1200/jco.2013.31.15_suppl.5009

Digital Object Identifier (doi)

• 10.1200/jco.2013.31.15_suppl.5009

Web Of Science Accession Number

Start Page

• 5009

End Page

• 5009

Volume

• 31

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2013

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N., De Souza, P. L., . . . Ryan, C. J. (2013). Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).. Journal of Clinical Oncology, 31(15_suppl), 5009. doi:10.1200/jco.2013.31.15_suppl.5009

Digital Object Identifier (doi)

• 10.1200/jco.2013.31.15_suppl.5009

Web Of Science Accession Number

Start Page

• 5009

End Page

• 5009

Volume

• 31

Issue

• 15_suppl

Place Of Publication